Today we presented 28-week data from the Phase 2 OLE study of ESK-001 in a late-breaking oral presentation at #EADVCongress. Learn more: https://lnkd.in/eNESZc4T
Alumis
Biotechnology Research
South San Francisco, California 4,833 followers
Transforming the lives of patients living with immune-mediated diseases using a precision approach.
About us
At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.
- Website
-
https://www.alumis.com
External link for Alumis
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- South San Francisco, California
- Type
- Privately Held
- Founded
- 2021
Locations
-
Primary
Get directions
611 Gateway Blvd
Suite 820
South San Francisco, California 94080, US
Employees at Alumis
-
Derrick Richardson
C-Suite Executive | Servant Leader | Mentor | Speaker | Change Agent | Advocate for the Underrepresented
-
William Coble
Transforming Quality Systems through Quality Intelligence
-
Vince Barella
-
Denise Winn, CPA (inactive)
Experienced Accounting and Finance Professional
Updates
-
We’re in Amsterdam for #EADVCongress to share Phase 2 STRIDE and 28-week OLE data on ESK-001 that continue to build a highly differentiated and best-in-class treatment profile for people with moderate-to-severe psoriasis. https://lnkd.in/dEHfhixC
-
Thank you to Nasdaq for recognizing our addition to the #Russell2000 Index. This milestone will enhance our visibility in the investment community as we work to advance our pipeline of treatments for immune-mediated diseases.
-
-
Our CEO, Martin Babler, will be sharing company highlights in a fireside chat today at 10:55 a.m. ET at the 2024 Cantor Fitzgerald Global Healthcare Conference. You can join us for the live webcast here: https://bit.ly/4glkUoN
-
-
The Alumis team had an amazing experience at the 2024 J.P. Morgan Corporate Challenge in San Francisco! We were proud to support Eat. Learn. Play., a local nonprofit dedicated to improving the lives of kids and families in Oakland. Running as a team, it was a blast hitting the pavement for such a meaningful cause at the world’s largest corporate running event! #JPMCC
-
-
Today we reported our second quarter 2024 financial results and provided a summary of recent corporate achievements and upcoming milestones. Learn more: https://bit.ly/4ck9oqs
-
-
Today we announced that patient dosing has commenced in the ONWARD Phase 3 clinical program evaluating ESK-001, an oral #TYK2 inhibitor, in moderate-to-severe Plaque #psoriasis. Topline data anticipated in 2026. Learn more: https://bit.ly/4c2rSvs
-
-
We are thrilled to announce our initial public offering, trading on Nasdaq under the ticker $ALMS! This achievement wouldn't have been possible without the relentless dedication of our incredible team, as well as the support of our Board of Directors and investors. Thank you to everyone who helped us reach this critical milestone in support of our mission to improve the lives of patients with immune-mediated diseases. #NasdaqListed
🧬 Transform therapies, reimagine lives. That’s exactly what Alumis does. 🌟 $ALMS is transforming the lives of patients living with immune-mediated diseases using a precision approach to develop oral therapies. 👏 In celebration of their listing on Nasdaq, Alumis joins us for the Opening Bell. Exciting! Stay tuned for more!
-
-
Today we announced the pricing of our initial public offering: https://bit.ly/3zwhdvh #NasdaqListed
-
-
Alumis’ clinical development team attended the EULAR - European Alliance of Associations for Rheumatology 2024 Congress earlier this month in Vienna! With the goal of driving progress in the clinical care of people with rheumatic diseases, the annual meeting brings together patients, health professionals, rheumatologists and industry partners to showcase the latest scientific breakthroughs in clinical, translational, and basic research. We were thrilled to be part of this meeting as we advance our #lupus clinical trial LUMUS! #EULAR2024
-